Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF82422 in patients with multiple system atrophy
jRCT2021210061Phase 2Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing Lu AF82422 with Placebo (2 arms). Primary endpoint: Change from baseline in UMSARS Part I and Part II total score at end of double-blind treatment. Started Mar 2022; status: active, not recruiting.
02
Drugs
amlenetug
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on jRCT2021210061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210061.